Calcium-activated chloride channel (CaCC) (hCLCA1/mCLCA3) blocker; reduces mucin synthesis and release in cell culture and animal models. Possesses anti-inflammatory actions via inhibition of cyclooxygenases and inhibits Cl-/HCO3- exchanger activity. Increases survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 414.34. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.25 mM||9.65 mL||48.27 mL||96.54 mL|
|1.25 mM||1.93 mL||9.65 mL||19.31 mL|
|2.5 mM||0.97 mL||4.83 mL||9.65 mL|
|12.5 mM||0.19 mL||0.97 mL||1.93 mL|
References are publications that support the biological activity of the product.
Walker et al (2006) Talniflumate increases survival in a cystic fibrosis mouse model of distal intestinal obstructuve syndrome. J.Pharmacol.Exp.Ther. 317 275 PMID: 16354791
Sanchez et al (1982) Action of a non-steroidal anti-inflammatory drug on gastric mucosa of rats. J.Appl.Toxicol. 2 42
Knight (2004) Talniflumate (Genaera). Curr.Opin.Invest.Drugs 5 557
If you know of a relevant reference for Talniflumate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Talniflumate, Talniflumate supplier, Cyclooxygenase, inhibitors, inhibits, chloride, channels, blockers, Chloride, hCLCA1/mCLCA3, COX, Oxygenases, Oxidases, Cl-/HCO3-, exchangers, CaCC, calcium-activated, Ca2+-Activated, Channels, 2510, Tocris Bioscience
Citations for Talniflumate
Citations are publications that use Tocris products.
Currently there are no citations for Talniflumate. Do you know of a great paper that uses Talniflumate from Tocris? Please let us know.
Reviews for Talniflumate
There are currently no reviews for this product. Be the first to review Talniflumate and earn rewards!
Have you used Talniflumate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Programmed Cell Death Poster
There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.